Hagenacker, Tim http://orcid.org/0000-0002-3631-3450
Maggi, Lorenzo
Coratti, Giorgia
Youn, Bora
Raynaud, Stephanie
Paradis, Angela D. http://orcid.org/0000-0001-5698-8802
Mercuri, Eugenio
Funding for this research was provided by:
Biogen
Article History
Received: 21 December 2023
Accepted: 29 July 2024
First Online: 2 September 2024
Declarations
:
: Tim Hagenacker received grants/research support from Biogen, Novartis, and Roche, and honoraria or consulting fees from Biogen, Novartis, and Roche. Lorenzo Maggi received a grant from Biogen and honoraria for speaking, and consulting fees or compensation for congress participations from Amicus Therapeutics, Biogen, Janssen Pharmaceutics, Roche, and Sanofi Genzyme. Giorgia Coratti has received honoraria for speaking and compensation for congress participation from AveXis, Biogen, BioLogix, Novartis, and Roche. Bora Youn and Angela D. Paradis are employees of BiogenĀ and may hold stock in the company. Stephanie Raynaud is a former employee of Biogen and may have heldĀ stock in the company at the time of the study. Eugenio Mercuri has served on advisory boards for SMA studies for AveXis, Biogen, Ionis, Novartis, and Roche; as Principal Investigator for ongoing Biogen/Ionis and Roche clinical trials; and has received funding from Famiglie SMA Italy, Italian Telethon, and SMA Europe.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.